SCHEDULE: AustralianSuper Discloses 5.7% Stake in ResMed

AustralianSuper Pty Ltd has reported a beneficial ownership of 5.7% in ResMed Inc.'s ordinary shares as of June 30, 2026.

Summary

• AustralianSuper Pty Ltd has filed a Schedule 13G, indicating it beneficially owns 8,276,381 ordinary shares of ResMed Inc.
• This holding represents 5.7% of the class of securities.
• The filing confirms sole voting and dispositive power over these shares.
• The acquisition and holding of these shares are stated to be in the ordinary course of business and not for the purpose of influencing control of ResMed Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but stable institutional holding without immediate strategic shifts.

Positives

• Significant institutional ownership by AustralianSuper Pty Ltd, a major superannuation fund.
• Clear disclosure of beneficial ownership, providing transparency to the market.
• The holding is stated to be in the ordinary course of business, suggesting a long-term investment perspective.

Negatives

• No specific negative financial or operational information is presented in this filing.
• The filing does not provide details on the acquisition cost or strategy behind the investment.

Risks

• Potential for future changes in AustralianSuper's holding, which could impact ResMed's stock price.
• As a significant shareholder, AustralianSuper's investment decisions could influence corporate governance or strategic direction, though the filing states no intent to influence control.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding ResMed's future performance. It solely reports on AustralianSuper's current ownership stake.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that significant institutional filings like this are common in the healthcare technology sector, reflecting investor confidence or strategic allocation by large funds. ResMed operates in a competitive market for sleep and respiratory care devices.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional investor's stake.
• Management: May influence strategic discussions if AustralianSuper decides to engage further, though current filing indicates no intent to influence control.

Next Steps

• Continued monitoring of AustralianSuper's ownership levels in ResMed Inc.
• Observation of any future filings by AustralianSuper or other significant institutional investors.

Key Dates

Keywords

ResMed, AustralianSuper, Schedule 13G, Institutional Ownership, Beneficial Ownership, Ordinary Shares, Securities